George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Asian Shares Mixed Despite US-China Trade Deal Optimism

Tue, 08th Jan 2019 08:58

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in Beijing.

The second day of negotiations coincided with an unannounced visit by North Korean leader Kim Jong Un, with some analysts saying China could use Kim's visit as a bargaining chip in the US trade talks.

China's Shanghai Composite index slid 0.26% to 2,526.46 while Hong Kong's Hang Seng index rose 0.15% to 25,875.45.

Japanese shares ended on a positive note after Amazon and Microsoft Corp fueled a second straight session of gains on Wall Street overnight.

The Nikkei average gained 165.07 points or 0.82% to finish at 20,204.04 while the broader Topix index closed 0.39% higher at 1,518.43.

Automaker Honda Motor rallied 3.2% and Toyota rose 1.2% while banks Mitsubishi UFJ Financial, Sumitomo Mitsui Financial and Mizuho Financial rose between 0.3% and 1.3%.

Takeda Pharmaceutical climbed 2.3% after completing its acquisition of Irish drugmaker Shire. Inpex and Japan Petroleum gained around 1% after crude oil prices rose more than 1% overnight.

Olympus Corp jumped 8.4% after Morgan Stanley upgraded the stock's rating to "overweight" from "equal-weight".

Seoul stocks fell as investors monitored the second day of trade talks between China and the US. The benchmark Kospi dropped 11.83 points or 0.58% to 2,025.27. Samsung Electronics lost 1.7% after it partnered with tech giant Apple Inc. to bring iTunes content to Samsung smart televisions.

On the data front, South Korea posted a current account surplus of USD5.06 billion in November, the Bank of Korea said - down from the USD9.19 billion surplus in October. The goods account surplus stood at USD7.97 billion, down from USD11.46 billion in November 2017.

Australian markets closed notably higher amid signs that Beijing and Washington may be inching closer toward a trade deal.

Traders shrugged off weak trade data showing that the country had a seasonally adjusted merchandise trade surplus of AUD1.925 billion in November, shy of expectations for a surplus of AUD2.175 billion and down from AUD2.316 billion in October.

The benchmark S&P/ASX 200 index rose 39.20 points or 0.69% to 5,722.40 while the broader All Ordinaries index ended higher by 38.80 points or 0.68% at 5,783.30.

Banks ANZ, NAB and Westpac rose between 0.9% and 1.2%. Waste management giant Bingo Industries soared 5.7% after it offered to sell its Sydney processing plant to address antitrust concerns related to the planned acquisition of Dial-aDump.

Gold miner Evolution lost 3.4%, St Barbara tumbled 5% and Northern Star Resources declined 2.6% as dovish comments from the Fed boosted investors' appetite for risk.

Sleep device maker ResMed advanced 1.4% after completing the USD225 million acquisition of US-based asthma and pulmonary specialist Propeller Health.

New Zealand shares rose modestly, with the benchmark S&P/NZX 50 index finishing up 15.11 points or 0.17% at 8,821.15.

U.S stocks rose overnight as the US and China resumed talks on their trade war and Federal Reserve Chair Jerome Powell said the central bank would be "flexible" in its approach to monetary policy.

The Dow Jones Industrial Average rose 0.4%, the tech-heavy Nasdaq Composite rallied 1.3% and the S&P 500 climbed 0.7%.

More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.